Log In
Print this Print this

Pollinex Quattro Birch

  Manage Alerts
Collapse Summary General Information
Company Allergy Therapeutics plc
DescriptionSubcutaneous birch allergy vaccine formulated with modified allergens, tyrosine and the toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPL)
Molecular Target
Mechanism of ActionVaccine; Immunotherapy
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsTreat birch pollen-induced seasonal allergic rhinitis
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today